This review summarizes practical approaches to prescribing, monitoring, and adjusting regional citrate anticoagulation (RCA) for patients undergoing continuous renal replacement therapy (CRRT). The authors emphasize treating RCA as an integrated CRRT prescription that coordinates citrate delivery and removal, individualized calcium replacement, CRRT fluid composition, and structured biochemical monitoring. The review highlights recent advances in citrate kinetics, calcium homeostasis, recognition of impaired citrate metabolism, metabolic complications, and systems-based safety considerations.
Randomized trials and meta-analyses continue to show that RCA prolongs filter or circuit life and reduces bleeding compared with systemic heparin anticoagulation. The available evidence has not demonstrated a mortality benefit with RCA. Recent work has refined understanding of citrate dosing, systemic citrate load, and first-pass citrate extraction. Studies also support individualized strategies for calcium replacement based on anticipated calcium losses in the effluent.
Safe implementation of RCA requires a coordinated prescription that includes:
Treating these elements as a single, integrated prescription facilitates optimization of circuit anticoagulation while preserving electrolyte and acid–base homeostasis.
The review supports assessment of baseline ionized calcium before initiating CRRT with RCA. Ongoing biochemical monitoring should be structured to detect trends in calcium, acid–base status, and markers relevant to citrate metabolism. Integration of lactate trends into the assessment is specifically recommended as part of evaluating citrate metabolism. Monitoring should permit timely recognition of four common clinical problems that require prescription adjustment.
Prescription adjustments for RCA should focus on four recurring clinical scenarios described in the review:
inadequate circuit anticoagulation: adjustments to citrate delivery or circuit parameters are considered to restore effective anticoagulation;
negative calcium balance: individualized calcium replacement should be adjusted based on anticipated effluent calcium losses and measured systemic ionized calcium to prevent hypocalcemia;
excessive bicarbonate generation from citrate metabolism: because citrate metabolism generates bicarbonate, CRRT fluid composition and citrate dose may need modification when patients develop metabolic alkalosis or unexpected increases in bicarbonate;
impaired citrate metabolism: when citrate clearance or metabolism is reduced, systemic citrate load may rise and require prompt recognition and management.
Specific numeric targets, stepwise dosing algorithms, and exact adjustment amounts were not reported in the abstract and are not available in the source text presented here.
The review places emphasis on recognizing impaired citrate metabolism and distinguishing true citrate accumulation from other metabolic effects of RCA. Incorporating lactate trends into the overall assessment is suggested as a practical aid: rising lactate may reflect impaired metabolism and warrants evaluation. The authors note that clinicians should integrate clinical, biochemical, and CRRT operational data to differentiate accumulation from expected metabolic consequences of citrate use.
Standardized protocols, structured laboratory monitoring, staff education, and integration of RCA workflows into CRRT operations are highlighted as central to safe implementation. The review recommends system-level measures to ensure consistent application of integrated prescriptions and rapid identification of complications. These systems-based interventions support effective anticoagulation while minimizing bleeding risk and metabolic or electrolyte disturbances.
Regional citrate anticoagulation is most effectively managed when citrate delivery and removal, calcium replacement, CRRT fluid selection, and operational parameters are coordinated within a single prescription. Recent advances have clarified citrate kinetics, individualized calcium needs, and strategies to recognize impaired citrate metabolism. Clinicians should prioritize baseline ionized calcium assessment, monitor lactate trends as part of citrate metabolism evaluation, individualize CRRT fluid selection, and distinguish true citrate accumulation from other metabolic effects. Adjustments should target four common scenarios: inadequate anticoagulation, negative calcium balance, excess bicarbonate generation, and impaired citrate metabolism. Finally, standardized protocols, structured monitoring, and staff training remain essential for safe RCA use.
Note: The abstract summarized here did not report specific numeric dosing recommendations, exact monitoring intervals, or detailed algorithms; those details were not provided in the source text available for this rewrite.